Lilly Korea announces KFDA approval of exenatide

Lilly Korea announce that the Korea Food and Drug Administration has approved exenatide as adjunctive therapy to improve blood sugar control in patients with type 2 diabetes who have not achieved adequate control on metformin and/or a sulfonylurea, two common oral diabetes medications.

Co-developed by Lilly and Company and Amylin Pharmaceuticals, Inc., exenatide is the first in a new class o...